0.9251  0.018 (1.96%)		05-16 16:00
Open: 0.8801 High: 1.06 Volume: 357,139		Pre. Close: 0.9073 Low: 0.8499 Market Cap: 5(M)

Short term
Mid term
Targets	6-month :	1.4	1-year :	1.63
Resists	First :	1.2	Second :	1.4
Pivot price	0.85
Supports	First :	0.85	Second :	0.63
MAs	MA(5) :	0.9	MA(20) :	0.81
	MA(100) :	0.93	MA(250) :	1.33
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	50.9	D(3) :	49.7
RSI	RSI(14): 57.4
52-week	High :	3.03	Low :	0.56

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ CHEK ] has closed below upper band by 32.0%. Bollinger Bands are 35.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	1.06 - 1.07	1.07 - 1.07
Low:	0.84 - 0.84	0.84 - 0.85
Close:	0.92 - 0.92	0.92 - 0.93

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. The company was incorporated in 2004 and is based in Isfiya, Israel.

Thu, 01 May 2025
Check-Cap Ltd. Delays Annual Report Filing - TipRanks

Tue, 15 Apr 2025
Check-Cap Faces Nasdaq Compliance Challenge and Announces Key Appointments - TipRanks

Thu, 26 Dec 2024
Check-Cap Ltd. Approves $6M Loan to Nobul AI Corp. for Expansion - TipRanks

Tue, 24 Dec 2024
Why Carbon Revolution Shares Are Trading Higher By Around 62%; Here Are 20 Stocks Moving Premarket - Benzinga

Mon, 25 Mar 2024
Nobul and Check-Cap announce definitive merger agreement - Investing.com

Mon, 08 Jan 2024
symbol__ Stock Quote Price and Forecast - CNN

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Shares Out	6 (M)
Shares Float	4 (M)
Held by Insiders	25 (%)
Held by Institutions	2.3 (%)
Shares Short	48 (K)
Shares Short P.Month	93 (K)

EPS	-2.15
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	2.94
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-33.3 %
Return on Equity (ttm)	-53.1 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-2.35
Qtrly Earnings Growth	0 %
Operating Cash Flow	-14 (M)
Levered Free Cash Flow	-10 (M)

PE Ratio	-0.44
PEG Ratio	0
Price to Book value	0.31
Price to Sales	0
Price to Cash Flow	-0.39

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.